Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next? - Université de Lorraine
Article Dans Une Revue Expert Opinion on Biological Therapy Année : 2021

Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?

Résumé

The use of biosimilars for the treatment of patients with chronic inflammatory bowel diseases (IBD) showed to be a valid strategy to reduce the economic burden of biologics on health-care costs and to increase patient access to treatment. However, the nocebo effect constitutes an important limitation to the wide use of biosimilars.
Fichier non déposé

Dates et versions

hal-04214723 , version 1 (22-09-2023)

Identifiants

Citer

Ferdinando d'Amico, Virginia Solitano, Laurent Peyrin-Biroulet, Silvio Danese. Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?. Expert Opinion on Biological Therapy, 2021, 21 (1), pp.47-55. ⟨10.1080/14712598.2020.1817374⟩. ⟨hal-04214723⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

More